IRIS
CECCHERINI SILBERSTEIN, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 69.619
AS - Asia 11.519
EU - Europa 9.137
SA - Sud America 1.766
AF - Africa 263
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 27
Totale 92.367
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 69.223
SG - Singapore 5.706
CN - Cina 1.954
IT - Italia 1.733
BR - Brasile 1.417
RU - Federazione Russa 1.329
DE - Germania 1.121
HK - Hong Kong 1.006
VN - Vietnam 904
UA - Ucraina 815
IE - Irlanda 800
SE - Svezia 696
FR - Francia 578
FI - Finlandia 509
GB - Regno Unito 479
BD - Bangladesh 466
PL - Polonia 449
KR - Corea 432
JP - Giappone 311
CA - Canada 214
IN - India 169
NL - Olanda 144
AR - Argentina 120
ID - Indonesia 119
AT - Austria 110
MX - Messico 104
ES - Italia 100
ZA - Sudafrica 74
TR - Turchia 64
BE - Belgio 61
EC - Ecuador 53
CZ - Repubblica Ceca 49
IQ - Iraq 48
CO - Colombia 45
PH - Filippine 45
PK - Pakistan 42
UZ - Uzbekistan 35
CL - Cile 33
VE - Venezuela 30
AU - Australia 27
CH - Svizzera 27
ET - Etiopia 27
PY - Paraguay 26
KE - Kenya 23
MA - Marocco 23
MY - Malesia 23
AE - Emirati Arabi Uniti 21
PE - Perù 20
JO - Giordania 19
LT - Lituania 19
DZ - Algeria 18
CM - Camerun 17
RO - Romania 17
EG - Egitto 16
EU - Europa 16
IR - Iran 16
JM - Giamaica 16
SA - Arabia Saudita 16
IL - Israele 15
KZ - Kazakistan 13
GR - Grecia 12
HN - Honduras 12
TW - Taiwan 12
UY - Uruguay 12
NG - Nigeria 11
NP - Nepal 11
PT - Portogallo 11
TN - Tunisia 11
DO - Repubblica Dominicana 10
AL - Albania 9
BG - Bulgaria 9
KG - Kirghizistan 9
NZ - Nuova Zelanda 9
TH - Thailandia 9
BO - Bolivia 8
CR - Costa Rica 8
DK - Danimarca 8
AO - Angola 7
AZ - Azerbaigian 7
HR - Croazia 7
HU - Ungheria 7
SC - Seychelles 7
OM - Oman 6
PA - Panama 6
RS - Serbia 6
XK - ???statistics.table.value.countryCode.XK??? 6
BB - Barbados 5
CI - Costa d'Avorio 5
LB - Libano 5
LK - Sri Lanka 5
LV - Lettonia 5
NO - Norvegia 5
PS - Palestinian Territory 5
TT - Trinidad e Tobago 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CY - Cipro 4
DM - Dominica 4
GE - Georgia 4
KH - Cambogia 4
MD - Moldavia 4
Totale 92.296
Salva come PNG Salva come JPEG
Città #
Woodbridge 17.829
Wilmington 17.454
Houston 14.247
Singapore 3.072
Fairfield 2.207
Ashburn 1.688
San Jose 1.460
Chandler 1.376
Ann Arbor 1.360
Hong Kong 981
Seattle 894
Beijing 802
Cambridge 719
Dublin 694
Jacksonville 664
Council Bluffs 641
Rome 576
Santa Clara 516
Medford 494
New York 436
Los Angeles 379
Dearborn 368
Kraków 359
The Dalles 315
Helsinki 297
Ho Chi Minh City 290
Tokyo 277
Hanoi 230
Lawrence 230
Moscow 224
Buffalo 207
Milan 178
Munich 165
San Diego 156
São Paulo 143
Lauterbourg 133
Menlo Park 125
Dallas 124
Nuremberg 116
Orem 110
London 104
Mülheim 103
Chicago 93
Jakarta 86
Phoenix 73
Zhengzhou 70
Boardman 67
Frankfurt am Main 65
Montreal 64
San Francisco 63
Creede 59
Brooklyn 58
Brussels 58
Redondo Beach 56
North Bergen 55
Vienna 55
Denver 52
Toronto 51
Warsaw 51
Johannesburg 47
Chennai 46
Atlanta 45
Palo Alto 43
Falls Church 42
Guangzhou 42
Lappeenranta 42
Redwood City 42
Rio de Janeiro 42
Amsterdam 41
Shanghai 40
Mexico City 38
Poplar 38
Naples 36
Cedarhurst 35
Columbus 35
Nanjing 35
Stockholm 35
Colorado Springs 34
Mountain View 34
Boston 33
Da Nang 33
Haiphong 32
Belo Horizonte 31
University Park 30
Brno 29
Dong Ket 29
Manchester 29
Norwalk 29
Verona 29
Kunming 27
Brasília 24
Madrid 24
Tashkent 24
Engelhard 23
Hefei 23
Washington 23
Bari 22
Hangzhou 22
Mumbai 22
Curitiba 21
Totale 75.170
Salva come PNG Salva come JPEG
Nome #
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 597
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 577
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 569
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 552
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 534
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 534
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 533
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 527
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 527
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 513
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 510
Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes 509
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 509
Virologic correlates of adherence to antiretroviral medications and therapeutic failure 506
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 506
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 490
Understanding HIV compartments and reservoirs 490
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 489
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 488
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 486
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 486
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 485
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 482
Novel drug resistance mutations in HIV: Recognition and clinical relevance 476
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 476
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 476
Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso 475
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 475
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 474
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 474
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 469
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 467
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients 466
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 466
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 464
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 461
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 461
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors 460
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 459
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 458
A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy 457
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 457
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning 451
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort 449
Incomplete APOBEC3G/F neutralization by HIV-1 Vif mutants facilitates the genetic evolution from CCR5 to CXCR4 usage 448
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 447
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy 446
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 446
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 445
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 445
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 444
The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors 442
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure 442
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin 442
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 442
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria 442
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 442
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 440
The use of human immunodeficiency virus resistance tests in clinical practice 440
Dynamics of NRTI resistance mutations during therapy interruption 439
Gene transfer in astrocytes: comparison between different delivering methods and expression of the HIV-1 protein Nef 439
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 439
Molecular dynamics and free energy studies on the wild-type and mutated hiv-1 protease complexed with four approved drugs: Mechanism of binding and drug resistance 438
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 437
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 436
The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A 435
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 435
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes 435
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype 434
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics 434
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study 434
Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation 434
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 431
HIV-Infected Late Presenter Patients 430
Molecular diversity of HIV in Albania 429
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 428
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 428
The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs 427
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 427
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 426
Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations 426
Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir 423
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 422
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 421
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 420
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 420
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district 420
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors 419
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 418
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 417
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data 417
Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients 416
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation 416
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 416
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 415
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 415
From current status to optimization of HCV treatment: Recommendations from an expert panel 415
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 415
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 415
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors 414
Totale 45.778
Salva come PNG Salva come JPEG
Categoria #
all - tutte 240.074
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 240.074
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021183 0 0 0 0 0 0 0 0 0 0 0 183
2021/20222.995 130 221 199 148 120 230 183 126 564 242 150 682
2022/20233.815 419 295 194 447 351 793 270 354 313 43 240 96
2023/20241.502 226 44 90 58 120 255 71 61 57 207 34 279
2024/20258.670 280 1.700 929 481 251 544 1.029 420 791 514 863 868
2025/202615.636 1.261 586 1.441 1.427 1.411 647 1.995 1.985 1.730 1.386 1.000 767
Totale 93.694